Non – Detection of HPV DNA in Prostatic Cancer and Benign Prostatic Hyperplasia: a case- control study in Kerman

Document Type: Original Article


1 Assistant Professor, Pathology and Stem Cells Research Center, Kerman University of Medical Sciences, Kerman, Iran

2 Professor of Pathology, Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

3 Researcher, Pathology and Stem Cells Research Center, Kerman University of Medical Sciences, Kerman, Iran

4 Assistant Professor, Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

5 Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran


Background: Different studies assessed the role of inflammation in malignancy of different organs. Prostatitis has been suggested as a cause of cancer and BPH. Till now, more than 100 types of human Papilloma virus (HPV) are recognized including low and high-risk groups for carcinogenesis. Among them HPV-16 and HPV-18 have shown further association with cancer. Regarding the presence of E6 and E7 in HPV and ability for modification of basal epithelial cells, related role in prostate cancer (as well as cervical and genital malignancies) is hypothesized. The aim of this study was to determine the association of HPV-16 and HPV-18 with prostate cancer and malignancy degree.
Methods: A total of 75 consecutive paraffin-embedded blocks including 50 samples with primary prostate cancer and 25 samples with benign prostate hyperplasia (BPH) as control were studied. Amplisense kit was used for replication at real-time polymerase chain reaction (PCR) to determine genotypes of HPV-16 and HPV-18. DNA purity was assessed by Nano Drop.
Results: The results of real-time PCR demonstrated that none of the samples of BPH and prostate cancer had amplification of HPV DNA.
Conclusion: The results revealed that HPV-16 and HPV-18 are not causes of prostate cancer.


  1. Carozzi F, Lombardi FC, Zendron P, Confortini M, Sani C, Bisanzi S, et al. Association of human papillomavirus with prostate cancer: analysis of a consecutive series of prostate biopsies. Int J Biol Markers 2004;19(4):257-61.
  2. Babaei M, Mousavi S, Toussy J. Cancer occurrence in old age: Results of a population-based cancer registry in Semnan, Iran. Asian Pac J Cancer Prev 2006;7(2):191-4.
  3. National Institute for Health and Clinical Excellence (NICE). Prostate cancer: diagnosis and treatment. Clinical guideline [CG175]; jan 8,2014. Available from:
  4. Wilt TJ, Ahmed HU. Prostate cancer screening and the management of clinically localized disease. BMJ 2013;346:f325.
  5. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013;158(10):761-9.
  6. Steger G, Corbach S. Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. J Virol 1997;71(1):50-8.
  7. Desaintes C, Demeret C. Control of papillomavirus DNA replication and transcription. Semin Cancer Biol 1996;7(6):339-47.
  8. Laimins LA. The biology of human papillomaviruses: from warts to cancer. Infect Agents Dis 1993;2(2):74-86.
  9. Thomas JT, Hubert WG, Ruesch MN, Laimins LA. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc Natl Acad Sci U S A 1999;96(15):8449-54.
  10. Aghakhani A, Hamkar R, Parvin M, Ghavami N, Nadri M, Pakfetrat A, et al. The role of human papillomavirus infection in prostate carcinoma. Scand J Infect Dis 2011;43(1):64-9.
  11. Ghasemian E, Monavari SH, Irajian GR, Jalali Nodoshan MR, Roudsari RV, Yahyapour Y. Evaluation of human papillomavirus infections in prostatic disease: a cross-sectional study in Iran. Asian Pac J Cancer Prev 2013;14(5):3305-8.
  12. Effert PJ, Frye RA, Neubauer A, Liu ET, Walther PJ. Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis: analysis of archival human prostate cancer specimens by differential polymerase chain reaction. J Urol 1992;147(1):192-6.
  13. Bergh J, Marklund I, Gustavsson C, Wiklund F, Grönberg H, Allard A, et al. No link between viral findings in the prostate and subsequent cancer development. Br J Cancer 2007;96(1):137-9.
  14. Singh N, Hussain S, Kakkar N, Singh SK, Sobti RC, Bharadwaj M. Implication of high risk human papillomavirus HR-HPV infection in prostate cancer in Indian population--a pioneering case-control analysis. Sci Rep 2015;5:7822.
  15. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res1992;52(21):5991-6.
  16. Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, Eiguchi K. Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol 2005;5:15.
  17. Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155(10):698-705.